Eubelius acted as transaction counsel on the EUR 5 Million investment in ViroVet NV by Biotech Fonds Vlaanderen NV, Agri Investment Fund CVBA, Gemma Frisius - Fonds KU Leuven NV, Vives II – Louvain Technology Fund NV, the Catholic University of Leuven and Aratana Therepeutics NV.
ViroVet focuses on the discovery, licensing and development of innovative vaccines and antiviral drugs to improve the health and value of livestock. With this investment, ViroVet aims to accelerate its research and development efforts and to launch its veterinary product portfolio.
The Eubelius team was led by Matthias Wauters, Felix Dobbelaere and Elias Van Marcke.
For more information, see: De Tijd, PMV AIF and Bio Flanders.